Adverum_Primary_Medium.png
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
18 mars 2024 16h05 HE | Adverum Biotechnologies, Inc.
- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - -...
Adverum_Primary_Medium.png
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
28 févr. 2024 16h05 HE | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly...
Adverum_Primary_Medium.png
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
12 févr. 2024 08h00 HE | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
08 févr. 2024 07h00 HE | Adverum Biotechnologies, Inc.
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and...
Adverum_Primary_Medium.png
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
05 févr. 2024 07h45 HE | Adverum Biotechnologies, Inc.
- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare...
Adverum_Primary_Medium.png
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
01 févr. 2024 17h30 HE | Adverum Biotechnologies, Inc.
- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with...
Adverum_Primary_Medium.png
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
29 janv. 2024 08h00 HE | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
07 déc. 2023 16h05 HE | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
28 nov. 2023 16h05 HE | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
09 nov. 2023 16h05 HE | Adverum Biotechnologies, Inc.
- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels...